PerkinElmer Inc. (PKI) To Go Ex-Dividend on October 12th
PerkinElmer Inc. (NYSE:PKI) announced a quarterly dividend on Wednesday, July 27th. Investors of record on Friday, October 14th will be paid a dividend of 0.07 per share on Thursday, November 10th. This represents a $0.28 dividend on an annualized basis and a yield of 0.50%. The ex-dividend date is Wednesday, October 12th.
Shares of PerkinElmer (NYSE:PKI) opened at 56.43 on Friday. The company has a 50-day moving average price of $54.47 and a 200-day moving average price of $53.37. PerkinElmer has a 12 month low of $39.50 and a 12 month high of $57.28. The stock has a market cap of $6.17 billion, a price-to-earnings ratio of 26.96 and a beta of 0.85.
PKI has been the topic of several research analyst reports. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a research report on Tuesday. Morgan Stanley set a $61.00 price target on PerkinElmer and gave the stock a “buy” rating in a research report on Friday, August 5th. BTIG Research initiated coverage on PerkinElmer in a research report on Friday, July 22nd. They set a “neutral” rating on the stock. Jefferies Group lifted their price target on PerkinElmer from $52.00 to $55.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. Finally, Mizuho lowered PerkinElmer from a “buy” rating to a “neutral” rating and set a $56.00 price target on the stock. in a research report on Friday, August 5th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the stock. PerkinElmer currently has a consensus rating of “Hold” and an average target price of $55.00.
In other PerkinElmer news, Director Kenton J. Sicchitano sold 15,189 shares of the business’s stock in a transaction on Wednesday, August 24th. The stock was sold at an average price of $54.87, for a total transaction of $833,420.43. Following the sale, the director now directly owns 43,160 shares in the company, valued at $2,368,189.20. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 38,095 shares of the business’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $55.00, for a total value of $2,095,225.00. Following the sale, the insider now owns 96,299 shares in the company, valued at $5,296,445. The disclosure for this sale can be found here. Company insiders own 2.30% of the company’s stock.
Hedge funds have recently bought and sold shares of the company. C M Bidwell & Associates Ltd. purchased a new stake in PerkinElmer during the second quarter worth approximately $167,000. Advisor Group Inc. purchased a new stake in PerkinElmer during the second quarter worth approximately $182,000. First Allied Advisory Services Inc. increased its stake in PerkinElmer by 5.3% in the second quarter. First Allied Advisory Services Inc. now owns 4,448 shares of the company’s stock worth $233,000 after buying an additional 224 shares during the last quarter. Mackenzie Financial Corp increased its stake in PerkinElmer by 3.7% in the second quarter. Mackenzie Financial Corp now owns 5,820 shares of the company’s stock worth $305,000 after buying an additional 209 shares during the last quarter. Finally, Analytic Investors LLC purchased a new stake in PerkinElmer during the second quarter worth approximately $332,000. Institutional investors own 90.50% of the company’s stock.
PerkinElmer Company Profile
PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental and laboratory markets. The Company’s operating segments include Human Health, Environmental Health and Corporate. The Human Health segment concentrates on developing diagnostics, tools and applications to help detect diseases earlier.
Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.